Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of 9MW3811 for Pathological Scars
ChiCTR2600129915Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 9MW3811 in Pathological scar (6 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoints: Scoring scales (mVSS, POSAS, DLQI and objective scar parameters) at Day 85 and Pharmacokinetic parameters of 9MW3811. Started Aug 2026; status: recruiting.
02
Drugs
9MW3811
03
Conditions
Pathological scar
Beyond the preview
Go deeper on ChiCTR2600129915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129915.